 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...27282930313233343536373839» |
- ||||| AMG 510 / Amgen
Fast track designation: First direct inhibitor of KRAS shows continued high level of activity @WCLC presentation & FDA Grants Fast Track Designation to AMG 510 for KRAS G12C+ NSCLC https://t.co/qoGlCwfGCs (Twitter) - Sep 10, 2019
- |||| AMG 510 / Amgen
NDA: KRAS inhibitörü AMG 510, 2019 Dünya Akciğer Konferansı'nda sunulan bir araştırma sonuçlarına göre, ileri evre, küçük hücreli dışı akciğer kanserli hastaların neredeyse tümünde, tümör kontrolü sağladı... https://t.co/d1hhWTp8pG #kanser #akciğerkanseri #AMG510 #WCLC19 @IASLC (Twitter) - Sep 9, 2019
- ||| AMG 510 / Amgen
Agree not needed here. Or for AMG 510 for KRAS G12C mut’n+ NSCLC, at least later line. (Twitter) - Sep 9, 2019
- ||||| AMG 510 / Amgen
P3 data: Dr. @rdoebele offering commentary on selpercatinib trial argues that trials of targeted therapy like this (& I would argue also AMG 510 for KRAS G12C mut’n+ NSCLC, at least in later line) don’t need phase 3 rand trials vs. chemo-based treatment. Agree. #WCLC19 #LCSM #OncoAlert (Twitter) - Sep 9, 2019
- | AMG 510 / Amgen
Next blockbuster drug amg510 (Twitter) - Sep 8, 2019
- ||| AMG 510 / Amgen
Tweet by @CharuAggarwalMD and @StephenVLiu AMG510 (Twitter) - Sep 8, 2019
- || AMG 510 / Amgen
1) A Ph3 trial can be done due to frequency of mutation 2) Tumours with this driver respond to ICIs (BRAFmut data is variable) to determine if we give 1L vs IO/chemo or IO (>50% ) or AMG510+IO, or is the role in 2L. Happy if we see long DoR but need to answer when and how. (Twitter) - Sep 8, 2019
- ||||| camrelizumab (INCSHR1210) / Incyte, AMG 510 / Amgen
Dear Colleagues, The @OncoAlert 🚨Tweet of the day🙌 Our #OncoAlert Highlights⚡️for @IASLC #WCLC19 Sunday 9/8/19📅 AMG510, KN189, MYSTIC & CAMRELIZUMAB Thank you🙏: @CharuAggarwalMD @BrendonStilesMD @StephenVLiu @Alfdoc2 @g_mountzios @Jbauml @s_couraud Sincerely @weoncologists (Twitter) - Sep 8, 2019
- |||| AMG 510 / Amgen
Clinical: Equally if not more excited for our patients with colorectal cancers who are also being studied as the other important cohort of patients with #KRASG12C. I did not imagine that I’d be paying attention to which KRAS mutation does my #CRCSM patient has. #Clinicaltrials #AMG510 (Twitter) - Sep 8, 2019
- ||| AMG 510 / Amgen
#OncoAlert AMG 510, the KRAS G12C inhibitor is everywhere on my Twitter timeline. It inhibits a previously elusive target and results in NSCLC are very good. Very happy to open this trial at the @JulesBordet CTCU on September 17th with @nuriakb as local PI https://t.co/j0WYtPGPbc (Twitter) - Sep 8, 2019
- ||| AMG 510 / Amgen
AMG510, finally starting to target Ras mutants. Good steps forward in lung cancer. (Twitter) - Sep 8, 2019
- ||||| AMG 510 / Amgen
Clinical: Dr. R. Govindan presents update on ph1 of KRAS G12C mut’n inhib AMG 510 in NSCLC. Impressive results: well tolerated, w/no DLTs up to 960 mg QD; DCR 96%, ORR 48% in evaluable pts. IMO, this is a turning point of effective Rx against tough & common mut’n. #WCLC19 #OncoAlert #LCSM (Twitter) - Sep 8, 2019
- ||| AMG 510 / Amgen
Overflow room for orals #WCLC19. Govindan showing data for amg510 for KRAS G12C. Impressive responses and durable. Not toxic either. Very encouraging (Twitter) - Sep 8, 2019
- |||| Mekinist (trametinib) / Novartis, AMG 510 / Amgen, trametinib
#WCLC19 Swimmers plot for AMG510 shown here. Responses occur quickly. NOTE: not all of these responses are confirmed. Need to see how durable these are. Remember our experience with MEKi in #KRAS #NSCLC - RR nice but not durable (trametinib plot shown) #OncoAlert (Twitter) - Sep 8, 2019
- |||| AMG 510 / Amgen
Clinical: AMG510 is one of the most exciting data @iaslc #WCLC19, 48% RR, 96% DCR, only one patient with PD. Small numbers but given the safety and tolerability, this represents an extremely viable option for KRASG12C mutant #NSCLC that is not an uncommon population (13%) @OncoAlert (Twitter) - Sep 8, 2019
- |||| AMG 510 / Amgen
#WCLC19 AMG510 study design. Early look. Impressive PK profile at 960mg with low IC90 #OncoAlert (Twitter) - Sep 8, 2019
- |||| AMG 510 / Amgen
#WCLC19 Highly anticipated update on AMG510 in #KRAS #NSCLC by Ramaswamy Govindan does not disappoint. High RR (48%, 54% at 960mg) and DCR of 100%! No DLTs! Amazing early data in a huge area of need. #OncoAlert (Twitter) - Sep 8, 2019
- ||||| AMG 510 / Amgen
Clinical: Trial design for AMG510. This presentation focuses on patients with NSCLC, but others were treated in trial #WCLC2019 #LCSM #OncoAlert (Twitter) - Sep 8, 2019
- ||||| AMG 510 / Amgen
Next up @govindan08 presents updated data on AMG510, an allosteric inhibitor of KRAS G12C. There were already exciting data presented at #ASCO19, so very interested in these updated results #WCLC2019 #LCSM #OncoAlert (Twitter) - Sep 8, 2019
- || AMG 510 / Amgen
Waiting for $AMG NCSLC updates on AMG510 to be presented at #WCLC19 Sunday 8, at 10:40AM CEST #KRASG12C (Twitter) - Sep 7, 2019
- ||| AMG 510 / Amgen
Excited about the #WCLC19 #LCSM good list of studies to watch.. I would add AMG-510 sunday AM oral session by Dr Govindan @govindan08 (Twitter) - Sep 2, 2019
- ||| AMG 510 / Amgen
Great choices! You've hit my highlights, minus presentation of AMG 510 update for KRAS G12C mut+ NSCLC. (Twitter) - Aug 29, 2019
- |||| AMG 510 / Amgen
Clinical: I would say given the efficacy of the new KRASG12C inhibitors (AMG510 and MTRX849) the standard of care will likely be changing very soon. After 35 years KRAS might not be as #undruggable as we thought. 5/10 NSCLC with PR is impressive (Twitter) - Aug 5, 2019
- | Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Aug 1, 2019
P1/2, N=158, Recruiting, Sponsor: Amgen
Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Aug 2020 --> Dec 2022
- | MRTX849 / Mirati, AMG 510 / Amgen
guggenheim: $MRTX AMG 510 provides additional external validation for MRTX849, but the competitive bar continues to rise as well possibility for MRTX849 to demonstrate best-in-class characteristics over AMG 510 $AMGN (Twitter) - Jul 31, 2019
- |||| TAK-788 / Takeda, AMG 510 / Amgen
Targeting the previously untargetable in NSCLC: @n8pennell reviews EGFR exon 20 directed agent TAK-788 with a 40% ORR, as well as positive signal from KRAS G12R inhibitor AMG510 #ASCOreview19 #CleClinicCancer (Twitter) - Jun 26, 2019
- || AMG 510 / Amgen
AMG 510 Active in KRAS+ NSCLC @cityofhope #lcsm https://t.co/x09s4aNfcE (Twitter) - Jun 16, 2019
- |||| AMG 510 / Amgen
@Alfdoc2 @PatelOncology AMG510 is extremely exciting. I see Novartis also has a trial for G12C. Any idea of upcoming trials on small molecules targeting other KRAS variants? These are the things that keep me up at night... (Twitter) - Jun 15, 2019
- | AMG 510 / Amgen
Journal: AMG 510 First to Inhibit "Undruggable" KRAS. (Pubmed Central) - Jun 14, 2019
Amgen's novel small-molecule inhibitor AMG 510 has become the first drug to successfully target a KRAS mutation in patients, according to findings presented at the 2019 American Society of Clinical Oncology Annual Meeting. In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRAS-mutant non-small cell lung cancer, and led to stable disease in most evaluable patients with colorectal or appendix cancer.
- ||| AMG 510 / Amgen
I think RegoNivo is intriguing. Need more data. Several ctDNA studies with remarkable results. This is here to stay. Then, triplet use in CRC. AMG 510 (Twitter) - Jun 12, 2019
- ||| MRTX849 / Mirati, AMG 510 / Amgen
.@oncoOuLungCA discusses the 2 direct KRAS G12C inhibitors in development, including AMG 510 and MRTX849 @UCIrvine #lcsm https://t.co/xlkFwse8FX (Twitter) - Jun 8, 2019
- |||| AMG 510 / Amgen
Abstract 3003: GREAT early data using AMG510 to target KRAS G12C #CRC and #NSCLC w/very promising early results. Excited to see more mature data and at higher doses. Can the elusive KRAS be finally targeted??? Congrats @mgfakih @DavidHongMD @MDAndersonNews #ASCO19 #endcancer (Twitter) - Jun 3, 2019
- ||||| AMG 510 / Amgen
Clinical: #ASCO19 excitement in room 406 for AMG 510 responses. Closer look here. Swimmer plot with lung on top (remember study is still ongoing). Big news. An area of immense need and a huge patient population. Remember only G12C. #LCSM #OncoAlert (Twitter) - Jun 3, 2019
- ||||| AMG 510 / Amgen
Clinical, Monotherapy: #ASCO19 Responses with AMG 510 monotherapy in pretreated #KRAS #NSCLC! Cases show clear regression. 5/10 responses. 4 confirmed. Only one with PD as best response. Data in CRC show some stability but no responses. #OncoAlert (Twitter) - Jun 3, 2019
- ||||| AMG 510 / Amgen
Clinical, PK/PD data: #ASCO19 Impressed by early safety data. None of the SAEs attributes to AMG 510. PK data show 24 hour levels waaay over the IC90. #OncoAlert #LCSM (Twitter) - Jun 3, 2019
- || AMG 510 / Amgen
#ASCO19 $AMGN AMG 510 #KRAS (Twitter) - Jun 3, 2019
- ||| AMG 510 / Amgen
@jbauml elevating tweeting skills here: simultaneously folllowing Phase I/DT orals🙇♀️ Impressive data of KRAS oral inhibitor AMG510 in #NSCLC #CRC #ASCO19 (Twitter) - Jun 3, 2019
- ||||| AMG 510 / Amgen
#ASCO19 Marian Fakih @cityofhope presenting the highly anticipated early look at AMG 510, a novel, oral #KRAS G12C inhibitor from @Amgen. It binds to the cysteine residue so not for all KRAS mutations. #LCSM #OncoAlert packed house... (Twitter) - Jun 3, 2019
- |||| AMG 510 / Amgen
AMG 510 in KRAS G12C NSCLC; 5/10 responses (Twitter) - Jun 3, 2019
- |||| AMG 510 / Amgen
AMG510 seems to be very well tolerated, no DLTs have been seen thus far #LCSM #ASCO19 (Twitter) - Jun 3, 2019
- |||| AMG 510 / Amgen
The KRAS G12C inhibitor AMG510 is also being presented in the DT oral abstracts session #LCSM #ASCO19 (Twitter) - Jun 3, 2019
- ||| Lumakras (sotorasib) / Amgen
Phase classification, Enrollment change, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Jun 3, 2019
P1/2, N=158, Recruiting, Sponsor: Amgen
In a phase I trial, AMG 510 elicited partial responses in half of evaluable patients with KRAS-mutant non-small cell lung cancer, and led to stable disease in most evaluable patients with colorectal or appendix cancer. Phase classification: P1 --> P1/2 | N=60 --> 158
- ||| AMG 510 / Amgen
Amgen AMG 510 site (@DavidHongMD) https://t.co/EfiPyMMgOQ (Twitter) - May 28, 2019
- ||| AMG 510 / Amgen
maybe NSCLC is more sensitive to AMG510 than CRC #ASCO19 #amg510 #KRASg12c (Twitter) - May 26, 2019
- |||| AMG 510 / Amgen
Clinical: #ASCO19 $AMGN AMG-510 in NSCLC, CRC &"one other" jaja N=22 Prior lines of tx: >3 5 Pts reported TRAEs (Gr 1 & 2), No DLTs cc @JacobPlieth (Twitter) - May 15, 2019
- ||| MRTX849 / Mirati, AMG 510 / Amgen
Comparison of AMG 510, MRTX849 and MRTX1257 - the leading KRAS G12C inhibitors $AMGN $MRTX #AACR19 #ASCO19 (Twitter) - May 15, 2019
- | AMG 510 / Amgen
Good choice of top abstracts @CharuAggarwalMD @weoncologists #OncoAlert .. i would also add AMG510 to the list (Twitter) - May 7, 2019
- || AMG 510 / Amgen
First ph1 data for AMG 510 - best in class (?) KRAS asset https://t.co/UGxBMADs2K #ASCO19 $AMGN $MRTX (Twitter) - Apr 17, 2019
- | Lumakras (sotorasib) / Amgen
Trial completion date, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Feb 1, 2019
P1, N=60, Recruiting, Sponsor: Amgen
Phase classification: P1 --> P1/2 | N=60 --> 158 Trial completion date: Aug 2020 --> Apr 2024
- ||| Lumakras (sotorasib) / Amgen
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov) - Sep 17, 2018
P1, N=60, Recruiting, Sponsor: Amgen
Trial completion date: Aug 2020 --> Apr 2024 Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Aug 2020 | Trial primary completion date: Mar 2020 --> Aug 2020